Literature DB >> 6464502

Metabolism of nabumetone (BRL 14777) by various species including man.

R E Haddock, D J Jeffery, J A Lloyd, A R Thawley.   

Abstract

Radiotracer methodology was used to study the metabolic fate of 4-(6-methoxy-2-naphthyl)-butan-2-one (nabumetone) after oral administration to rats, mice, rabbits, dogs, rhesus monkeys and healthy human subjects. Parent compound was not detected in plasma and urine and the major circulating metabolite in all species was identified as 6-methoxy-2-naphthylacetic acid, a compound known to possess anti-inflammatory activity. Metabolites were mainly excreted in urine from which four principal metabolites were isolated and identified by mass spectrometry and independent synthesis. Pathways involving O-demethylation, reduction of the ketone group and oxidation of the butanone side-chain to acetic acid occurred in all species, but the ratios of the metabolic end-products tended to be species dependent. In the rat about half of the administered nabumetone was oxidized to the pharmacologically active acid metabolite.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6464502     DOI: 10.3109/00498258409151419

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  13 in total

1.  Effects of the prodrug nabumetone, and its active metabolite, 6-MNA, on human and rat gastric mucosal prostanoids and platelet function.

Authors:  J Y Jeremy; D P Mikhailidis; M A Barradas; R M Kirk; P Dandona
Journal:  Drugs       Date:  1990       Impact factor: 9.546

2.  Nabumetone. Evidence for the lack of enterohepatic circulation of the active metabolite 6-MNA in humans.

Authors:  M A Brett; G Buscher; E Ellrich; W H Greb; H J Kurth; G Rülander; B Schmerenbeck; R E Haddock; A R Thawley
Journal:  Drugs       Date:  1990       Impact factor: 9.546

3.  Reductive metabolism of nabumetone by human liver microsomal and cytosolic fractions: exploratory prediction using inhibitors and substrates as marker probes.

Authors:  Kaori Matsumoto; Tetsuya Hasegawa; Junichi Koyanagi; Tamiko Takahashi; Masayuki Akimoto; Kenji Sugibayashi
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2015-06       Impact factor: 2.441

4.  A pharmacokinetic study of the active metabolite of nabumetone in young healthy subjects and older arthritis patients.

Authors:  M J Kendall; M C Chellingsworth; R Jubb; A R Thawley; N A Undre; D C Kill
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

5.  Nonsteroidal anti-inflammatory drug therapy and gastric side effects. Does nabumetone provide a solution?

Authors:  P Dandona; J Y Jeremy
Journal:  Drugs       Date:  1990       Impact factor: 9.546

Review 6.  Clinical pharmacokinetics of nabumetone. The dawn of selective cyclo-oxygenase-2 inhibition?

Authors:  N M Davies
Journal:  Clin Pharmacokinet       Date:  1997-12       Impact factor: 6.447

7.  Carbon-carbon bond cleavage in activation of the prodrug nabumetone.

Authors:  Fatbardha Varfaj; Siti N A Zulkifli; Hyoung-Goo Park; Victoria L Challinor; James J De Voss; Paul R Ortiz de Montellano
Journal:  Drug Metab Dispos       Date:  2014-02-28       Impact factor: 3.922

8.  Nabumetone. A reappraisal of its pharmacology and therapeutic use in rheumatic diseases.

Authors:  H A Friedel; H D Langtry; M M Buckley
Journal:  Drugs       Date:  1993-01       Impact factor: 9.546

Review 9.  Nabumetone: therapeutic use and safety profile in the management of osteoarthritis and rheumatoid arthritis.

Authors:  Thomas Hedner; Ola Samulesson; Peter Währborg; Hans Wadenvik; Kjell-Arne Ung; Anders Ekbom
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 10.  Nabumetone. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in rheumatic diseases.

Authors:  H A Friedel; P A Todd
Journal:  Drugs       Date:  1988-05       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.